ACLA Sues FDA To Block New LDT Oversight - Food and Drugs Law - Food, Drugs, Healthcare, Life Sciences

ACLA Sues FDA To Block New LDT Oversight

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.

Explore Firm Details

Of Counsel Benjamin Zegarelli shared key insights with MD+DI on the American Clinical Laboratory Association's (ACLA's) lawsuit against the FDA for their laboratory-developed test (LDT) ruling.

United States Food, Drugs, Healthcare, Life Sciences

Of Counsel Benjamin Zegarelli shared key insights with MD+DI on the American Clinical Laboratory Association's (ACLA's) lawsuit against the FDA for their laboratory-developed test (LDT) ruling.

Benjamin commented on previous LDT enforcement, stating since 1988, "LDTs and the clinical laboratories that develop and commercialize them have had to comply with CLIA and state laws relating to laboratory operations but were not required to comply with FDA's medical device regulations due to the agency's historical policy of enforcement discretion for LDTs."

SOURCE

MD+DI

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.